Bionano Genomics Relative Valuation
Relative valuation compares Bionano’s financial metrics (like price-to-sales, enterprise value-to-revenue, and price-to-book) against similar companies in the same industry.
The LSEG (London Stock Exchange Group) assigned a Relative Valuation rating of 10 to BNGO (highest rating). A rating of 10 suggests Bionano is trading at a steep discount, even though its technology, intellectual property, and clinical traction may justify a much higher valuation.
Bionano Genomics is considered extremely undervalued compared to its peers. In plain terms, the market price doesn’t reflect the company’s potential, assets, or future earnings.
According to Alpha Spread, Bionano’s a 94% undervaluation.
Market Data 
Markets 
AI
